<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944264</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY02000298</org_study_id>
    <nct_id>NCT04944264</nct_id>
  </id_info>
  <brief_title>A Mind-Body Intervention for Diabetes Management: A Pilot Study</brief_title>
  <official_title>SMART Management of Type 1 Diabetes - Modifying Glucose Metabolism With an Online Mind-body Intervention: A Feasibility and Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Managing type 1 diabetes is stressful. Stress physiology influences glucose metabolism.&#xD;
      Continuous glucose monitors allow us to track glucose variability in the real-world&#xD;
      environment. Managing stress and cultivating resiliency should improve diabetes management&#xD;
      and reduce glucose variability. The study was designed as a randomized prospective cohort&#xD;
      pre-post study with wait time control. Participants were adult type 1 diabetes patients who&#xD;
      used a continuous glucose monitor and recruited from an academic endocrinology practice. The&#xD;
      intervention was the Stress Management and Resiliency Training (SMART) program conducted over&#xD;
      8 sessions over web-based video conference software. The primary outcome measures were:&#xD;
      Glucose variability, the Diabetes Self-Management questionnaire (DSMQ) and the&#xD;
      Connor-Davidson Resiliency (CD-RISC) instrument.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: It was hypothesized that the course on videoconferencing platform would deliver&#xD;
      similar effects on quality of life as has been seen in the past from on-site courses, and&#xD;
      that the intervention would reduce glucose variability and improve resiliency Design: This&#xD;
      pilot was designed as a prospective cohort pre-post intervention study with subjects&#xD;
      randomized to an immediate start or wait time control The study was approved by the Committee&#xD;
      for the Protection of Human Subjects at Dartmouth Hitchcock Medical Center and Dartmouth&#xD;
      College. All participants provided written informed consent.&#xD;
&#xD;
      Intervention: The Stress Management and Resiliency Training (SMART) program&#xD;
      (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is&#xD;
      designed to cultivate both the early recognition of stress in the mind and body, develop&#xD;
      skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is&#xD;
      an 8 session program, typically run in a live group setting. In this study's case it was&#xD;
      delivered via a videoconferencing platform. This was done both as a means of testing&#xD;
      delivering this service in a rural setting where patient might be geographically distant or&#xD;
      isolated and to accommodate the need for social distancing during the COVID-19 pandemic.&#xD;
&#xD;
      Recruitment: Recruitment occurred through the Dartmouth-Hitchcock Medical Center (DHMC)&#xD;
      endocrinology clinic and the endocrinologists working there. Candidates were included if they&#xD;
      had type 1 diabetes and used a continuous glucose monitor. Candidates were excluded if they&#xD;
      were &lt; 21 years old and could not give informed consent. To allow for controlled analysis, on&#xD;
      presentation at each site, participants were randomly assigned to one of two cohorts: 1)&#xD;
      immediate start (A) and 2) delayed start (B). The immediate arm began at the next available&#xD;
      class. The delayed start group began 4 weeks later. During their wait, this group was offered&#xD;
      usual care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose (mg/dl)</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Glucose levels measured via a continuous glucose monitor (CGM) in order to determine Mean, Median and Standard Deviation over 10 days total for both sleep time (10 PM to 6 AM) and active time (6 AM to 10 PM); data is automatically collected every 15 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose standard deviation (SD)</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Glucose levels measured via a continuous glucose monitor (CGM) in order to determine Mean, Median and Standard Deviation over 10 days total for both sleep time (10 PM to 6 AM) and active time (6 AM to 10 PM); data is automatically collected every 15 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Management Indicator (GMI)</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Glucose Management Indicator (GMI) approximates the laboratory A1C level expected based on average glucose measured using continuous glucose monitoring (CGM) values. Average glucose is derived from at least 12 days of CGM data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Form - 6 Dimensions (SF-6D)</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Range 0 - 1. Higher is better an econometric preference-based index derived from 11 items of the SF-36, which are combined into six dimensions of health, with four to six levels each. It is used to estimate quality of life. The SF-6D describes 18,000 different health states.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes Self-Management Questionnaire (DSMQ)</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Range 0 - 10. Higher is better The DSMQ is a 16-item questionnaire to assess self-care activities associated with glycemic control in patients with diabetes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Connor-Davidson Resilience Scale (CD-RISC)</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Range 0 - 25. Higher is better The CD-RISC assesses resilience and constitutes a 25 item questionnaire scored on a 5-point likert scale (rated 0-4). The total score ranges from 0-100, with higher scores indicating greater resilience.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implementation barriers</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Qualitative feedback from participants regarding implementation barriers of the SMART-3RP program for patients with type 1 diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implementation Facilitators</measure>
    <time_frame>duration of study, approximately 6 months</time_frame>
    <description>Qualitative feedback from participants regarding Implementation Facilitators of the SMART-3RP program for patients with type 1 diabetes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Stress, Psychological</condition>
  <condition>Stress, Physiological</condition>
  <arm_group>
    <arm_group_label>Immediate start</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Behavioral: Stress Management and Resiliency Training (SMART) program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed start</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wait time control</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress Management and Resiliency Training (SMART) program</intervention_name>
    <description>The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.</description>
    <arm_group_label>Delayed start</arm_group_label>
    <arm_group_label>Immediate start</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of type 1 diabetes (diagnosis â‰¥ 5 years) treated exclusively with insulin by&#xD;
             multiple (&gt;2 daily) injections or pump&#xD;
&#xD;
          -  no prior use of a continuous glucose monitor; ages &gt; 21&#xD;
&#xD;
          -  ability to read and speak English at the high school level&#xD;
&#xD;
          -  ability and willingness to come to the clinic once per week for a mind-body group&#xD;
             intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  major psychiatric illness&#xD;
&#xD;
          -  severe diabetes complications under active treatment (i.e., retinal laser or injection&#xD;
             treatments, dialysis, foot ulcers)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  an inability to attend weekly mind-body group sessions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>05055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>James E. Stahl</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

